SALT LAKE CITY--(BUSINESS WIRE)--Alucent Biomedical - a privately held biotechnology company founded to transform the way vascular disease is treated, today announced the appointment of six new members to its executive leadership team. The new members bring decades of experience in the areas of biotechnology, cardiovascular disease and product development to the company.
The additions to the executive leadership team include:
- Katalin Kauser, M.D., Ph.D, D.Sc., vice president of biology, joins Alucent Biomedical after 20 years of experience in the biotechnology and pharmaceutical industry with such firms as Global Blood Therapeutics, Boehringer Ingelheim, Actelion, and Bayer, specializing in cardiovascular biology, pharmacology, and drug development.
- Bruce Krattenmaker, vice president of regulatory affairs, has more than 30 years of experience leading global regulatory and clinical affairs for start-up and large medical device companies. He most recently served as vice president of global regulatory affairs for Allergan, where he led worldwide regulatory affairs for the company’s entire $3 billion medical device franchise.
- Julie Logan, vice president of clinical affairs, has more than 20 years of experience in the interventional cardiovascular field conducting clinical trials on behalf of many start-up medical device companies, developing cutting-edge cardiovascular products and performing complex coronary, vascular and structural interventions.
- Scott Mayfield, CPA, vice president of finance and administration, brings more than 20 years of experience managing finance, accounting and human resources for CRBard and Boston Scientific and for growing life science companies, such as Catheter Innovations, InnerDyne, Perseon, and Catheter Technology Corp., funded by venture capital, private equity and angel investors.
- Jane Ren, Ph.D., vice president of research & development and chief technology officer, joins Alucent with 20 years of experience developing interventional medical devices and drug delivery technologies. Her previous positions included VP at Boston Scientific, and Chief Technology Officer at CeloNova BioSciences. During her tenure at these companies, she led cross-functional teams for both interventional oncology and interventional cardiology platforms, throughout all phases of development and commercialization.
- Kevin Warner, Ph.D., vice president of pharmaceutical development, joins Alucent Biomedical with 15 years of pharmaceutical development experience. He was most recently at Allergan, Inc., where he held roles of increasing responsibility in pharmaceutical product development, including serving most recently as director of small molecule development.
“The in-depth expertise our executive team brings to the table will accelerate Alucent’s progress towards the goal of bringing Natural Vascular Scaffolding™ treatment to patients suffering from vascular disease,” said Myles Greenberg, M.D., president and chief executive officer of Alucent Biomedical. “I am excited to be working with such an accomplished group of executives to advance the company’s groundbreaking technology.”
About Alucent Biomedical, Inc.
Alucent Biomedical, Inc. is a privately held biotechnology company headquartered in Salt Lake City, Utah and is the first company to bring a novel, locally delivered biotechnology treatment to a market traditionally dominated by medical device solutions. Alucent was founded by Avera Health to develop and market Natural Vascular Scaffolding (NVS). NVS is a first-of-a-kind combination drug-device therapy designed to assist the body in naturally opening and maintaining arterial patency. www.alucentbiomedical.com